• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 感染后恢复期人类血清抗体的高分辨率分析。

High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection.

机构信息

Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.

Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.

出版信息

Sci Rep. 2022 May 31;12(1):9045. doi: 10.1038/s41598-022-12032-8.

DOI:10.1038/s41598-022-12032-8
PMID:35641545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152668/
Abstract

Long-term antibody responses to SARS-CoV-2 have focused on responses to full-length spike protein, specific domains within spike, or nucleoprotein. In this study, we used high-density peptide microarrays representing the complete proteome of SARS-CoV-2 to identify binding sites (epitopes) targeted by antibodies present in the blood of COVID-19 resolved cases at 5 months post-diagnosis. Compared to previous studies that evaluated epitope-specific responses early post-diagnosis (< 60 days), we found that epitope-specific responses to nucleoprotein and spike protein have contracted, and that responses to membrane protein have expanded. Although antibody titers to full-length spike and nucleoprotein remain steady over months, taken together our data suggest that the population of epitope-specific antibodies that contribute to this reactivity is dynamic and evolves over time. Further, the spike epitopes bound by polyclonal antibodies in COVID-19 convalescent serum samples aligned with known target sites that can neutralize viral activity suggesting that the maintenance of these antibodies might provide rapid serological immunity. Finally, the most dominant epitopes for membrane protein and spike showed high diagnostic accuracy providing novel biomarkers to refine blood-based antibody tests. This study provides new insights into the specific regions of SARS-CoV-2 targeted by serum antibodies long after infection.

摘要

针对 SARS-CoV-2 的长期抗体反应主要集中在全长刺突蛋白、刺突蛋白的特定结构域或核衣壳蛋白上。在这项研究中,我们使用高密度肽微阵列来代表 SARS-CoV-2 的完整蛋白质组,以鉴定 COVID-19 已康复病例在诊断后 5 个月时血液中存在的抗体所针对的结合位点(表位)。与早期(<60 天)评估表位特异性反应的先前研究相比,我们发现核衣壳蛋白和刺突蛋白的表位特异性反应已经收缩,而膜蛋白的反应则扩大了。尽管全长刺突蛋白和核衣壳蛋白的抗体滴度在数月内保持稳定,但我们的数据表明,有助于这种反应的表位特异性抗体群体是动态的,并且随着时间的推移而演变。此外,COVID-19 恢复期血清样本中多克隆抗体结合的刺突表位与已知的可中和病毒活性的靶位一致,这表明维持这些抗体可能提供快速的血清免疫。最后,针对膜蛋白和刺突蛋白的最主要表位具有很高的诊断准确性,为改进基于血液的抗体检测提供了新的生物标志物。这项研究提供了感染后很长时间内针对血清抗体的 SARS-CoV-2 特定区域的新见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/315acc1bb3fd/41598_2022_12032_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/5b3123ed2a32/41598_2022_12032_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/5dced234f060/41598_2022_12032_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/7fa338c62101/41598_2022_12032_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/73e3e653933c/41598_2022_12032_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/10528d46bd10/41598_2022_12032_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/315acc1bb3fd/41598_2022_12032_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/5b3123ed2a32/41598_2022_12032_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/5dced234f060/41598_2022_12032_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/7fa338c62101/41598_2022_12032_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/73e3e653933c/41598_2022_12032_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/10528d46bd10/41598_2022_12032_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a62/9156789/315acc1bb3fd/41598_2022_12032_Fig6_HTML.jpg

相似文献

1
High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection.SARS-CoV-2 感染后恢复期人类血清抗体的高分辨率分析。
Sci Rep. 2022 May 31;12(1):9045. doi: 10.1038/s41598-022-12032-8.
2
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.SARS-CoV-2 核衣壳结合抗体的交叉反应性及其对 COVID-19 血清学检测的影响。
Viruses. 2022 Sep 14;14(9):2041. doi: 10.3390/v14092041.
3
High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.高通量检测 SARS-CoV-2 刺突蛋白靶向抗体在纵向恢复期血浆样本中的存在。
Transfusion. 2021 May;61(5):1377-1382. doi: 10.1111/trf.16318. Epub 2021 Feb 18.
4
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.人类感染 SARS-CoV-2 后 S 蛋白反应性 IgG 和记忆 B 细胞的产生包括对 S2 亚基的广泛反应性。
mBio. 2020 Sep 25;11(5):e01991-20. doi: 10.1128/mBio.01991-20.
5
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
6
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.COVID-19 患者在出现血清转换之前使用门诊获得的 COVID-19 恢复期血浆。
Front Immunol. 2021 Sep 14;12:739037. doi: 10.3389/fimmu.2021.739037. eCollection 2021.
7
Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19.COVID-19 急性和恢复期患者对 SARS-CoV-2 膜蛋白的抗体反应。
Front Immunol. 2021 Aug 4;12:679841. doi: 10.3389/fimmu.2021.679841. eCollection 2021.
8
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
9
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.康复一年后 COVID-19 患者对 SARS-CoV-2 的中和抗体水平下降。
Front Immunol. 2021 Jun 16;12:708523. doi: 10.3389/fimmu.2021.708523. eCollection 2021.
10
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.

引用本文的文献

1
Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.用于合理开发具有增强交叉反应性疫苗的肽免疫阵列。
PLoS One. 2025 Sep 4;20(9):e0330741. doi: 10.1371/journal.pone.0330741. eCollection 2025.
2
μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints.μSARS2芯片:一种基于肽的微阵列,用于基于免疫指纹评估新冠肺炎预后。
ACS Pharmacol Transl Sci. 2025 Feb 21;8(3):871-884. doi: 10.1021/acsptsci.4c00727. eCollection 2025 Mar 14.
3
The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.

本文引用的文献

1
EPIphany-A Platform for Analysis and Visualization of Peptide Immunoarray Data.EPIphany - 一个用于肽免疫阵列数据分析与可视化的平台。
Front Bioinform. 2021 Jul 7;1:694324. doi: 10.3389/fbinf.2021.694324. eCollection 2021.
2
Broad betacoronavirus neutralization by a stem helix-specific human antibody.广谱β冠状病毒通过茎螺旋特异性人抗体中和。
Science. 2021 Sep 3;373(6559):1109-1116. doi: 10.1126/science.abj3321. Epub 2021 Aug 6.
3
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.SARS-CoV-2变异株与SARS-CoV交叉中和背后的B细胞基因组学
血清/血浆蛋白质组学对 SARS-CoV-2 诊断和预后的影响。
Int J Mol Sci. 2024 Aug 8;25(16):8633. doi: 10.3390/ijms25168633.
4
Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.使用新冠肺炎患者血清的蛋白质组学研究趋势:文献计量分析
Curr Med Chem. 2025;32(12):2275-2290. doi: 10.2174/0109298673286915240329063441.
5
The Secretory IgA Response in Human Milk Against the SARS-CoV-2 Spike Is Highly Durable and Neutralizing for At Least 1 Year of Lactation Postinfection.人乳中针对 SARS-CoV-2 刺突的分泌型 IgA 反应具有高度持久性和中和作用,至少在感染后 1 年的哺乳期内有效。
Breastfeed Med. 2023 Aug;18(8):602-611. doi: 10.1089/bfm.2023.0117.
6
The secretory IgA (sIgA) response in human milk against the SARS-CoV-2 Spike is highly durable and neutralizing for at least 1 year of lactation post-infection.人乳中针对新冠病毒刺突蛋白的分泌型免疫球蛋白A(sIgA)反应具有高度持久性,且在感染后至少1年的哺乳期内都具有中和作用。
medRxiv. 2023 May 26:2023.05.19.23290192. doi: 10.1101/2023.05.19.23290192.
Cell. 2021 Jun 10;184(12):3205-3221.e24. doi: 10.1016/j.cell.2021.04.032. Epub 2021 Apr 24.
4
Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19.不同严重程度 COVID-19 患者的 B 细胞 repertoire 动态变化和交叉反应性应答的出现。
Cell Rep. 2021 May 25;35(8):109173. doi: 10.1016/j.celrep.2021.109173. Epub 2021 May 9.
5
SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.SARS-CoV-2 血清中和测定:用于全新病毒的传统工具。
Viruses. 2021 Apr 10;13(4):655. doi: 10.3390/v13040655.
6
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.基于肽微阵列的 SARS-CoV-2 抗体反应分析鉴定出具有潜在诊断测试开发价值的独特表位。
Eur J Immunol. 2021 Jul;51(7):1839-1849. doi: 10.1002/eji.202049101. Epub 2021 May 7.
7
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.来自 1051 名 COVID-19 患者的 SARS-CoV-2 刺突蛋白线性表位图谱。
Cell Rep. 2021 Mar 30;34(13):108915. doi: 10.1016/j.celrep.2021.108915. Epub 2021 Mar 12.
8
Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与地方性和季节性β冠状病毒的血清学交叉反应性
J Clin Immunol. 2021 Jul;41(5):906-913. doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.
9
Genomic characterization and evolution of SARS-CoV-2 of a Canadian population.加拿大人群中 SARS-CoV-2 的基因组特征和进化。
PLoS One. 2021 Mar 4;16(3):e0247799. doi: 10.1371/journal.pone.0247799. eCollection 2021.
10
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.人类对急性 SARS-CoV-2 感染的抗体反应的广度和功能。
PLoS Pathog. 2021 Feb 26;17(2):e1009352. doi: 10.1371/journal.ppat.1009352. eCollection 2021 Feb.